Clinical trials: First Relapse
Esophagus Squamous Cell Carcinoma (SCC), Metastatic Cancer
Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma
Esophageal or esophageal-gastric junction squamous cell cancer has dismal prognosis. And still no promising chemotherapeutic drugs is existed.
- Trial name
- DOSE (NCT03585673)
- Testing
- Docetaxel-PM, Oxaliplatin
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Sung Yong Oh
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).
- Trial name
- NCT04849910
- Testing
- VOR33, Mylotarg
- Where
- 15 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Vor Biopharma
Steroid-Sensitive Nephrotic Syndrome
Rituximab in the First Episode of Paediatric Nephrotic Syndrome
The study will be a randomized, open-label trial in children with the initial episode of SSNS and whose state of complete remission after received standard prednisolone, to determine whether rituximab (a single intravenous…
- Trial name
- NCT05850546
- Testing
- Rituximab, Corticosteroid
- Where
- 3 sites in China
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Fudan University
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML)…
- Trial name
- NCT04243785
- Testing
- BTX-A51, Azacitidine
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Edgewood Oncology Inc.
NHL, Adult, AML, Adult Recurrent
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
This Trial is an open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with AML and NHL who previously received standard treatment or are…
- Trial name
- NCT05758610
- Testing
- ETH-155008
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shengke Pharmaceuticals (Jiangsu) Limited, China
Solid Tumor, Adult
Phase 1a Study to Evaluate Immunogenicity of ASV®
This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV® AGEN2017 with QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as…
- Trial name
- NCT03673020
- Testing
- ASV® AGEN2017 + QS-21 Stimulon® adjuvant
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Agenus Inc.
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase II trial compares the impact of brentuximab vedotin and nivolumab after radiation to standard of care high dose chemotherapy (HDT)-autologous stem cell transplant (ASCT) in standard-risk patients with classic Hodgkin…
- Trial name
- NCT07572123
- Testing
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection
- Volunteers
- 374 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
This phase II trial is studying how well giving UCN-01 together with topotecan works in treating patients with small cell lung cancer that relapsed or progressed after previous chemotherapy.
- Trial name
- NCT00098956
- Testing
- topotecan hydrochloride, 7-hydroxystaurosporine
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT02561962
- Testing
- AMG 224
- Where
- 5 sites in United States, Australia
- Volunteers
- 42 people
- Sponsor
- Amgen
Richter Syndrome
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
The STELLAR trial will assess the effect of acalabrutinib taken in combination with CHOP-R compared to taking CHOP-R alone in patients with newly diagnosed Richter's Syndrome (RS).
- Trial name
- STELLAR (NCT03899337)
- Testing
- Acalabrutinib, Cyclophosphamide, Doxorubicin
- Where
- 17 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- University of Birmingham
Multiple Myeloma at First Relapse
Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse
This is a single-arm, prospective, non-interventional, real-world study to observe and evaluate the efficacy and safety of selinexor in combination with daratumumab and dexamethasone in patients with multiple myeloma at first…
- Trial name
- NCT05559788
- Volunteers
- 34 people
- Sponsor
- Fu chengcheng PhD
Lymphoma, Non-Hodgkin
Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma
- Trial name
- NIVEAU (NCT03366272)
- Testing
- Nivolumab, Rituximab, Gemcitabine
- Where
- 77 sites in Austria, Belgium and 6 more
- Volunteers
- 348 people
- Sponsor
- Universität des Saarlandes
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
This is a FIH, single center, open label, non-randomized, single-arm, Phase I clinical trial to evaluate the safety and tolerability of CD5 CAR T (CT125B) cells in subjects with relapsed or refractory T-cell acute lymphoblastic…
- Trial name
- NCT05487495
- Testing
- CD5 CAR T (CT125B)
- Where
- China
- Sponsor
- Beijing Boren Hospital
Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
In spite of high initial response rate after a first line treatment by R-polychemotherapy, cutaneous but also extra-cutaneous recurrences occur after 2 years in about half of the patients with PCBCL-LT.
- Trial name
- REV-LEG (NCT01556035)
- Testing
- Lenalidomide
- Where
- 24 sites in France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Bordeaux
Relapsing Remitting Multiple Sclerosis
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy.
- Trial name
- PREFERMS (NCT01623596)
- Testing
- Fingolimod, Disease Modifying therapy
- Where
- 123 sites in United States, Puerto Rico
- Volunteers
- 881 people
- Sponsor
- Novartis Pharmaceuticals
First or Second Recurrence of Glioblastoma
Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma
In this study with a modified 3+3 dose finding design, a safe and tolerable dose of TKI258 in patients with relapsed glioblastoma should be established.
- Trial name
- TKI258 (NCT01972750)
- Testing
- Dovitinib
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- PD Dr. Martin Glas
Acute Myeloid Leukemia
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
Long term disease-free survival (DFS) of patients with acute myeloid leukemia (AML) is still poor. Recently, so-called "targeted therapy" for cancer has been introduced to the treatment of patients with AML.
- Trial name
- PAZOPANIB-AML (NCT01361334)
- Testing
- Pazopanib
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Muenster
Ovarian Cancer
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
This phase I/II trial will determine the recommended dose and activity of BNC105P for patients with partially platinum sensitive ovarian cancer in first or second relapse.
- Trial name
- NCT01624493
- Testing
- Carboplatin, Gemcitabine, BNC105P
- Where
- 6 sites in United States, Australia and 1 more
- Sponsor
- Hoosier Cancer Research Network
Advanced Malignant Neoplasm
First-in-Human Study of KO-947 in Non-Hematological Malignancies
This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological…
- Trial name
- NCT03051035
- Testing
- KO-947
- Where
- 5 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- Kura Oncology, Inc.
Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and best dose of veliparib and topotecan hydrochloride and to see how well they work in treating patients with solid tumors, ovarian cancer that has come back or does not respond to…
- Conditions
- Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01012817
- Testing
- Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
- Where
- 15 sites in United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)